These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35253777)

  • 1. Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders.
    Zhu S; Bäckström D; Forsgren L; Trupp M
    J Parkinsons Dis; 2022; 12(4):1169-1189. PubMed ID: 35253777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders.
    Nilsson J; Constantinescu J; Nellgård B; Jakobsson P; Brum WS; Gobom J; Forsgren L; Dalla K; Constantinescu R; Zetterberg H; Hansson O; Blennow K; Bäckström D; Brinkmalm A
    Mov Disord; 2023 Feb; 38(2):267-277. PubMed ID: 36504237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model.
    Song J; Kim J; Lee MJ; Ahn JH; Lee DY; Youn J; Chung MJ; Kim Z; Cho JW
    Parkinsonism Relat Disord; 2022 May; 98():32-37. PubMed ID: 35447488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
    Ayton S; Hall S; Janelidze S; Kalinowski P; Palmqvist S; Belaidi AA; Roberts B; Roberts A; Stomrud E; Bush AI; Hansson O
    Mov Disord; 2022 May; 37(5):993-1003. PubMed ID: 35137973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.
    van Rumund A; Aerts MB; Esselink RAJ; Meijer FJA; Verbeek MM; Bloem BR
    BMC Neurol; 2018 May; 18(1):69. PubMed ID: 29764386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
    Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
    Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
    Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
    J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics.
    Magdalinou NK; Noyce AJ; Pinto R; Lindstrom E; Holmén-Larsson J; Holtta M; Blennow K; Morris HR; Skillbäck T; Warner TT; Lees AJ; Pike I; Ward M; Zetterberg H; Gobom J
    Parkinsonism Relat Disord; 2017 Apr; 37():65-71. PubMed ID: 28214264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations.
    Paviour DC; Price SL; Jahanshahi M; Lees AJ; Fox NC
    Mov Disord; 2006 Jul; 21(7):989-96. PubMed ID: 16602104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.